unimportant decoration Nano-scale droplet illustration

BlueWillow’s Scientific Advisory Board

unimportant decoration

Robin Isaacs, M.D.

Dr. Isaacs was Chief Medical Officer of Entasis Therapeutics for four years. Prior, he held positions of increasing responsibility at Merck & Co., Inc, most recently serving as Vice President and Therapeutic Area Head, Vaccine Clinical Research. During his 18 years at Merck, Dr. Isaacs was involved with the worldwide development, regulatory submission, and approval of several anti-infective, antiviral, and vaccine products. He holds a M.B., B.H.B and an M.D. from the University of Auckland.

Akiko Iwasaki, Ph.D.

Dr. Iwasaki is a Waldemar Von Zedtwitz Professor at the Yale University Department of Immunobiology and Department of Molecular Cellular and Developmental Biology. She is currently an Investigator at the Howard Hughes Medical Institute. Dr. Iwasaki’s research focuses on the mechanisms of immune defense against viruses on mucosal surfaces, and her laboratory explores the relationship between viral infections and adaptive immunity. She holds a B.S. and a Ph.D. from the University of Toronto. Dr. Iwasaki completed her Postdoctoral Fellowship at the National Institutes of Health Intramural Research Program.

Steve Projan, Ph.D.

Dr. Projan is a Principal at Beat the Reaper, LLC. Previously, he served as a Senior Vice President of R&D in the Infectious Diseases & Vaccines Innovative Medicines unit (iMED) at MedImmune, where he led the strategy, prioritization and advancement of the company’s infectious disease and vaccine portfolio. Prior to MedImmune, Dr. Projan served as Vice President and Global Head of Infectious Diseases at the Novartis Institutes for Biomedical Research. He previously spent 15 years at Wyeth in roles of increasing responsibility, most recently as Vice President of Biological Technologies. He holds a B.S. from the Massachusetts Institute of Technology, as well as an M.A. and Ph.D. from Columbia University.